Maravai LifeSciences(MRVI) Prnewswire·2025-04-21 00:10Core Viewpoint - A securities class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial reporting during the Class Period from August 7, 2024, to February 24, 2025 [1]. Group 1: Allegations Against Maravai - The lawsuit claims that Maravai lacked adequate internal controls over financial reporting related to revenue recognition [2]. - It is alleged that Maravai inaccurately recognized revenue on certain transactions during fiscal 2024 [2]. - The complaint states that Maravai's goodwill was overstated, leading to misleading positive statements about the company's business and prospects [2]. Group 2: Lead Plaintiff Process - Investors in Maravai have until May 5, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - A lead plaintiff acts on behalf of all class members and is typically the investor or small group with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is encouraging Maravai investors who have suffered significant losses to contact them for more information [4]. - The firm has a global reputation for excellence and has recovered billions for victims of fraud and corporate misconduct [4].